What to Know About Pancreatic Disorders and IBD
Although inflammatory bowel disease (IBD) starts in the gut, it doesn’t always stay there. According to a 2015 study in the journal Inflammatory Bowel Disease, up to 47% of people with IBD will develop what are called “extraintestinal manifestations,” or EIMs. That means the disease ranges outside of the gut and causes problems in other tissues or organs. Not only are EIMs common, but many people experience more than one of them. That same 2015 study found that up to a quarter of IBD patients who develop an EIM will have more than one.
The skin, joints, and eyes are among the most common sites of these be...
Source: TIME: Health - April 5, 2023 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized Gut health Source Type: news
Forcing Canadians to switch from life-changing drugs saves governments millions. Do patients pay a price?
Ontario is the eighth Canadian jurisdiction to switch patients with Crohn's disease and other conditions from life-changing biologic drugs to more cost-effective 'biosimilars.' Both options are considered effective, and the swap saves millions. But should patients be forced to make the change? (Source: CBC | Health)
Source: CBC | Health - April 1, 2023 Category: Consumer Health News Tags: News/Health Source Type: news
U.S. sues Walmart for firing deli worker with Crohn's disease
Walmart Inc has been sued by the U.S. Equal Employment Opportunity Commission (EEOC), which on Tuesday accused the largest U.S. retailer of illegally firing a North Carolina deli worker with Crohn's disease. The EEOC said Walmart violated the Americans with Disabilities Act by dismissing Adrian…#walmartinc #eeoc #northcarolina #crohn #walmart #adriantucker #charlotte #statesville #melindadugas #bentonville (Source: Reuters: Health)
Source: Reuters: Health - March 28, 2023 Category: Consumer Health News Source Type: news
Should You Buy The Botox Maker Over Johnson & Johnson Stock?
We believe that AbbVie stock (NYSE: ABBV) is currently a better pick than its industry peer, Johnson & Johnson stock (NYSE: JNJ), given its better growth prospects. Although AbbVie is trading at 4.8x trailing revenues compared to 4.2x for J&J, this gap in valuation looks justified, given the…#abbvie #johnsonjohnson #jnj #remicade #allergan #humira #crohn #botox #rinvoq #abbvierevenue (Source: Reuters: Health)
Source: Reuters: Health - March 21, 2023 Category: Consumer Health News Source Type: news
‘We’ll look back and say that this was a bargain.’ Takeda reveals first data from its $4 billion autoimmune disease pill
In an intermediate-stage clinical study of 259 people with moderate-to-severe plaque psoriasis, the highest dose of the daily pill completely cleared itchy and painful patches of skin in one-third of the patients after 12 weeks. “We’re offering the potential for a functional cure,” Andrew Plump,…#andrewplump #takeda #boston #nimbustherapeutics #neworleans #plump #crohns #nimbus #tyk2 #bristolmyerssquibb (Source: Reuters: Health)
Source: Reuters: Health - March 18, 2023 Category: Consumer Health News Source Type: news
Upadacitinib Shows Positive Endoscopic Outcomes in Crohn's Disease Upadacitinib Shows Positive Endoscopic Outcomes in Crohn's Disease
Already FDA approved for ulcerative colitis, upadacitinib improves endoscopic response versus placebo in people with Crohn ' s disease, research shows.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 16, 2023 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Crohn's Disease Remission Rates Higher With Vedolizumab: Study Crohn's Disease Remission Rates Higher With Vedolizumab: Study
Findings may influence physicians to select vedolizumab over anti-TNF therapy as a first-line biologic for Crohn ' s disease.MDedge News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 10, 2023 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Nearly 1 in 3 Patients With IBD Affected by Skin Lesions Nearly 1 in 3 Patients With IBD Affected by Skin Lesions
No significant difference was found in skin lesion prevalence between patients with ulcerative colitis and Crohn ' s disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 9, 2023 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
Breakthrough for tens of thousands of Crohn's sufferers
Upadactinib is now poised to become available on the NHS for the 200,000 people whose lives are blighted by its painful and embarrassing symptoms. (Source: the Mail online | Health)
Source: the Mail online | Health - March 9, 2023 Category: Consumer Health News Source Type: news
Bitcoin Linked to QuadrigaCX Moves for First Time in 3 Years
Five bitcoin wallets attributed to defunct crypto exchange QuadrigaCX have curiously moved funds for the first time since the firm’s bankruptcy three years ago. The movements were identified by blockchain sleuth ZachXBT, who said on Twitter that 104 BTC ($1.75 million) was transferred on Dec. 17.…#twitter #ey #magdalenagronowska #coindesk #gronowska #geraldcotten #crohns #jenniferrobertson #cotten #netflix (Source: Reuters: Health)
Source: Reuters: Health - March 8, 2023 Category: Consumer Health News Source Type: news
Ileocecal Resection Possible First-line Option in Early Crohn's Ileocecal Resection Possible First-line Option in Early Crohn's
Patients with early ileocecal Crohn ' s disease who undergo ileocecal surgery remain off drug treatment 5 years later.MDedge News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 7, 2023 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
New STELARA ® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, March 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn’s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.1,2 These data are a part of Janssen’s 22 oral and poster ...
Source: Johnson and Johnson - March 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
IBD: More Patients on Vedolizumab vs Anti-TNFs at 2 Years IBD: More Patients on Vedolizumab vs Anti-TNFs at 2 Years
Vedolizumab showed a higher overall 1- and 2-year persistence of use compared with two anti –tumor necrosis factor inhibitors in both Crohn ' s disease and ulcerative colitis.MDedge News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 4, 2023 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
DNA Panels Could Predict Endoscopic Response to Biologics in CD DNA Panels Could Predict Endoscopic Response to Biologics in CD
Peripheral blood biomarkers in development that use DNA methylation could predict endoscopic response to treatment with adalimumab, vedolizumab, and ustekinumab for patients with Crohn ' s disease.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 4, 2023 Category: Drugs & Pharmacology Tags: Gastroenterology News Source Type: news
TREMFYA ® (guselkumab) Demonstrates a Differentiated Binding Mechanism from Risankizumab in In Vitro Studies
SPRING HOUSE, PENNSYLVANIA, March 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced additional results from in vitro MODIF-Y studies, which continue to support a hypothesis that not all IL-23 inhibitors are the same by demonstrating a differentiated binding mechanism for TREMFYA® (guselkumab) from risankizumab. Findings show that guselkumab is able to dose-dependently bind to CD64+a myeloid cells,1 the predominant source of IL-23-driven inflammation in the gut.2,b Data comprise one of Janssen’s 22 oral and poster presentations at the 18th Congress of the European Crohn’s and Col...
Source: Johnson and Johnson - March 3, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
